ScreenerHero

LSTA Lisata Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · lisata.com
1.210USD-3.97%Mkt Cap: 13.07M $P/E: —

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational prod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap13.07M USD
Enterprise Value206.23K USD
Revenue (TTM)100.00K USD
Gross Profit100.00K USD
Net Income (TTM)-16.59M USD
Revenue/Share0.01 USD
Last Price1.210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.04
PEG118.40
EV/EBITDA-0.01
EV/Revenue2.06
P/S130.73
P/B1.34
EPS (TTM)-1.61
EPS (Forward)-1.16
52W Range
0.98755% of range5.070
52W High5.070 USD
52W Low0.9875 USD
Profitability
Gross Margin100.00%
Oper. Margin-16426.00%
EBITDA Margin0.00%
Profit Margin-9756.47%
ROE-111.65%
ROA-93.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.95M USD
CapEx (TTM)28.00K USD
FCF Margin-8100.25%
FCF Yield-61.96%
Net Debt-10.44M USD
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity0.00
Current Ratio3.69
Quick Ratio3.56
Book Value/Sh0.90 USD
Cash/Share1.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateSep 15, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.10.80M
Float6.61M
Insiders22.26%
Institutions13.41%
Short Interest
Short Ratio0.3d
Short % Float2.22%
Short % Out.1.83%
Shares Short164.95K
Short (prev mo.)89.87K
Technical
SMA 501.412 (-14.3%)
SMA 2003.078 (-60.7%)
Beta0.94
S&P 52W Chg16.45%
Avg Vol (30d)389.36K
Avg Vol (10d)53.84K
Technical Indicators
RSI (14)36.3
MACD-0.0882
MACD Signal-0.0676
MACD Hist.-0.0206
BB Upper1.872 USD
BB Middle1.540 USD
BB Lower1.209 USD
BB Width43.07%
ATR (14)0.1617 USD
Vol Ratio (20d)1.06x